

SUMMARY

A national survey of 1937 members of the Canadian Celiac Association was conducted by mail questionnaire in June 1989 to study problems in diagnosing and managing celiac disease (CD) and dermatitis herpetiformis. Although 82% of the 1294 respondents were biopsied, 14% were diagnosed by their dramatic response to the gluten-free diet. Fifteen percent of biopsy-proven respondents saw five or more doctors before CD was diagnosed. Mean delays in diagnosis ranged from 5.8 (± 10.9) years for those with nausea or vomiting to 13.9 (± 14.5) years for those with headache or migraine.

RÉSUMÉ

En juin 1989, un questionnaire postal a permis de mener une enquête nationale auprès de 1937 membres de l'Association cœliaque canadienne afin d'étudier les problèmes diagnostiques et thérapeutiques reliés à la maladie cœliaque et à la dermatite herpétiforme. Malgré la biopsie effectuée chez 82% des 1294 répondants, 14% ont vu leur diagnostic confirmé par leur réponse remarquable suite à une diète sans gluten. Quinze pourcent des répondants dont le diagnostic avait été prouvé par biopsie avaient vu au moins cinq médecins avant d'en arriver au diagnostic. Les délais diagnostiques moyens ont varié de 5.8 à 10.9 ans pour les patients qui présentaient des nausées et des vomissements et de 13.9 à 14.5 ans pour les patients présentant des céphalées ou des migraines.

Can Fam Physician 1992;38:2604-2608.

Celiac Disease and Dermatitis Herpetiformis

National survey indicates delays in diagnosis

A. GEORGE F. DAVIDSON, MD, FRCPC
J. ALEXANDER CAMPBELL, PHD

THE CLINICAL EFFECTS OF CELIAC disease (CD) vary widely but typically include diarrhea, weight loss, and malabsorption of nutrients.

Some persons with the disease also have other seemingly unrelated conditions, such as edema, tetany, fatigue, and irritability.^{1,2} Other conditions, such as dermatitis herpetiformis, lactose intolerance, and aphthous ulcerations, often accompany CD.³ Thus, celiac patients may present to almost any hospital department, and diagnosis may be delayed or missed unless clinicians are aware of CD's many manifestations.

Changes in the clinical features of the disease over time have been noted,⁴ and some have suggested that CD is underdiagnosed.⁵ Even after diagnosis, the treatment of CD and dermatitis herpetiformis (DH), requiring lifelong adherence to the gluten-free diet – although seemingly simple – is a source of concern to many.⁶ In 1960, a study found that 81% of patients remained undiagnosed for 5 years after the onset of their

symptoms.⁷ A more recent study suggested⁸ that the delay has been markedly reduced, but other researchers⁹ found a mean delay of 10.6 \pm 11 years before diagnosis. Thus, although the problem of delay in diagnosis has been identified, little progress has been made toward its solution.

To determine the problems facing its members, the Canadian Celiac Association decided to conduct a national survey by mail questionnaire. The main objectives were to determine:

- the length and nature of the diagnostic process;
- the occurrence of CD, or symptoms suggesting CD, in family members;
- the response of celiac patients to diet;
- the nature of advice received; and
- the problems of dietary compliance.

This report presents the results of the diagnostic aspects of the first objective. Data on the dietary aspects have been reported elsewhere.¹⁰

METHOD

A comprehensive questionnaire was developed by a survey committee comprised of representatives from the Medical and Nutrition Advisory Boards and members of the Canadian Celiac Association. The questionnaire consisted

.....
Dr Davidson is a Professor in the Department of Pediatrics at the British Columbia Children's Hospital in Vancouver. **Dr Campbell**, a food and nutrition consultant in Ottawa, is Chairman of the Canadian Celiac Association's Survey Committee.

Table 1. Duration of symptoms experienced by biopsy-proven respondents before diagnosis of celiac disease

SYMPTOM	DELAYS IN DIAGNOSIS					NO. OF RESPONDENTS
	MEDIAN (YEARS)	MEAN (YEARS)	SD (YEARS)	RANGE		
				MINIMUM (MONTHS)	MAXIMUM (YEARS)	
Diarrhea	1.9	6.6	11.7	1	75	774
Abdominal pain	2.0	8.0	12.4	1	65	583
Gas or belching	2.5	8.4	13.0	1	74	629
Fatigue or lethargy	2.0	7.9	12.6	1	79	688
Bloating	2.0	7.9	12.4	1	79	770
Nausea or vomiting	1.0	5.8	10.9	1	65	334
Lack of appetite	1.0	6.2	12.7	1	70	330
Skin rash (DH)	4.0	10.3	13.0	1	57	155
Headache or migraine	10.0	13.9	14.5	1	62	204

of 43 questions, about half of which were medical. It was pre-tested on subjects of varying age and background for readability and ease of completion. Most questions required specific answers rather than being open-ended.

The questionnaire was mailed in June 1989 to 1937 members of the Association across Canada who had CD or DH. For persons younger than 18 years, we requested that the questionnaire be filled out by a parent or guardian. Strict confidentiality was maintained.

Cross-tabulations for biopsy-proven and non-biopsy-proven respondents were examined for all variables. Most data are given for biopsy-proven respondents.

RESULTS

Of 1937 questionnaires distributed, 1294 (67%) were returned and analyzed. Of the respondents, 93% reported that they had CD and 7% DH. Of those claiming to have CD, 82% were biopsy-proven. Female respondents comprised 74% of the total, and the female to male ratio was 2.82:1.

The reasons for diagnosis of CD given by those respondents who had no biopsy proof of CD were diagnosis before biopsy procedure was available (6%), dramatic response to the gluten-free diet (14%),

self-diagnosis (3%), CD "confirmed" by doctor (11%), and DH (2%).

Respondents were asked whether they had experienced any of nine separate symptoms before they were "officially" diagnosed as having CD, and for how long they believed they had had these symptoms. Mean delays for biopsy-proven respondents varied from 5.8 ± 10.9 years for those reporting nausea or vomiting to 13.9 ± 14.5 years for those reporting headache or migraine. Most median delays were 1 to 3 years (Table 1). The proportion of biopsy-proven respondents experiencing symptoms was generally similar for male and female patients, but the number experiencing more than 5 years' delay was somewhat higher for female respondents for some symptoms (Table 2).

When asked how many doctors they had consulted about their problem, 25% of 960 biopsy-proven respondents said one doctor, 29% two doctors, 17% three doctors, 12% four doctors, 6% five doctors, 6% six to 10 doctors, and 3% more than 10 doctors.

When respondents were asked what other diagnoses were given for their condition before they were diagnosed with CD, they identified a variety of conditions (Table 3). Virus, influenza, and bacterial infection were most often reported.

Table 2. Proportion of male and female biopsy-proven respondents experiencing delays in diagnosis of celiac disease

SYMPTOMS	ALL BIOPSY-PROVEN RESPONDENTS		MORE THAN 5 YEARS' DELAY	
	MALE	FEMALE	MALE	FEMALE
	N (%)	N (%)	N (%)	N (%)
Diarrhea	207 (83)	567 (72)	58 (23)	184 (23)
Abdominal pain	133 (82)	450 (82)	45 (28)	178 (33)
Gas or belching	151 (84)	478 (85)	57 (32)	189 (34)
Fatigue or lethargy	158 (83)	530 (85)	45 (24)	208 (33)
Bloating	142 (83)	500 (84)	50 (29)	190 (32)
Nausea or vomiting	57 (72)	275 (86)	15 (19)	76 (24)
Lack of appetite	65 (76)	265 (83)	9 (11)	67 (21)
Skin rash (DH)	57 (75)	98 (81)	21 (28)	54 (45)
Headache or migraine	31 (79)	173 (78)	14 (36)	115 (52)

DISCUSSION

The response to this survey compares favourably with that reported elsewhere.¹¹ The female to male ratio of 2.82:1 reflects the membership of the Canadian Celiac Association rather than the true ratio for CD in the Canadian population. A preponderance of female patients has also been reported in other surveys.¹²

Although 82% of respondents had biopsies, it is a matter of concern that 14% of respondents' diagnoses were based on a dramatic response to the gluten-free diet and 11% were "confirmed" by doctors by some other means. As has been recently reemphasized,¹³ no sure diagnosis of celiac disease can be made without identifying the characteristic histological picture of the duodenal-jejunal mucosa. This point needs to be more widely recognized.

Less delay in diagnosis was encountered with nausea or vomiting and lack of appetite than with the other symptoms. Particularly long delays were reported with headache and migraine symptoms, suggesting that it was difficult to relate headache or migraine symptoms to CD. The ranges in delays indicated that some

individuals had had the symptoms all their lives. With lack of appetite, skin rash, and headache and migraine symptoms, the proportion of female respondents reporting delays of more than 5 years tended to be greater than that of male respondents. The reason for this is unclear but may be related to menstrual and related disorders. The fact that 21% to 52% of biopsy-proven female respondents and 11% to 36% of biopsy-proven male respondents with these conditions have had diagnosis delayed for more than 5 years is a matter of real concern. It seems that, in spite of advances in modern diagnostic techniques, little progress has been made in hastening the diagnosis of CD.

When asked to indicate which conditions were diagnosed before CD diagnosis, respondents rated anemia, stress, nervous condition, and irritable bowel most frequently. Much more attention must be given, particularly to the finding of anemia, to a possible early indicator of CD. Considerable confusion of CD with irritable bowel syndrome appeared to have occurred in both the biopsy-proven and non-biopsy-proven groups.

Because so many doctors were consulted before CD was diagnosed, it was

obvious that many doctors did not understand the disease. In this regard, many respondents expressed deep concerns about the problems they had encountered in being properly and promptly diagnosed. They considered it quite unacceptable to have to see so many doctors to be diagnosed properly and to be given such a variety of diagnoses. There was a feeling among respondents that many doctors were not informed about the disease or were unaware of the need for a biopsy; that they did not know that adults were subject to CD as well as children; and that they were unaware that treatment of CD and DH requires strict adherence to the gluten-free diet.

Delay in diagnosing CD has resulted in long periods of ill health for many respondents. Little emphasis seems to have been placed on this aspect of the disease. Numerous screening methods have been proposed.¹⁴⁻¹⁷ As Guandalini et al¹³ have suggested, it may be time for a change in diagnosis. The diagnostic accuracy of estimating antigliadin antibodies is quite high. New patients with CD lack IgG antigliadin antibodies, and few patients who have IgA antigliadin antibodies do not have CD. The absence of IgG antigliadin antibodies and the presence of IgA antigliadin antibodies together are a reliable indication of CD. Much greater emphasis must be placed on developing appropriate screening methods.

CONCLUSION

Serious delays still exist in the diagnosis of CD. There is an urgent need to make physicians more aware of the symptoms of CD and to investigate and apply procedures that will hasten and simplify diagnosis. ■

Acknowledgments

We acknowledge the assistance of Dr Murray MacKinnon of Vancouver and the advice of other members of the survey committee: Dr M.C. Champion, University of Ottawa; Ms Mavis Molloy, University of British Columbia; Ms Lynne Mortimer-Bankier, University of Ottawa; Ms Mary Smith, Canadian Celiac Association, Ottawa; and Ms Rosie Wartecker, Canadian Celiac Association, Toronto. This study, sponsored by the Canadian Celiac Association of

Mississauga, Ont, with significant financial contributions from the Ottawa Chapter of the Canadian Celiac Association, was presented in part at the meeting of the Royal College of Physicians and Surgeons in Quebec City in September 1991.

Table 3. Diagnoses of diseases made before celiac disease was diagnosed

DIAGNOSIS	RESPONDENTS (%)	
	BIOPSY-PROVEN (N = 686)	NOT BIOPSY-PROVEN (N = 145)
Anemia	47	30
Stress	45	39
Nervous condition	41	39
Irritable bowel	34	43
Stomach ulcer	23	14
Food allergy	19	32
Colitis	13	23
Menstrual problems	13	17
Edema	9	8
Gallstones	9	10
Diverticulitis	6	9
Dermatitis herpetiformis	4	5
Other	36	39

Requests for reprints to: Dr J.A. Campbell, c/o Canadian Celiac Association, 6519B Mississauga Rd, Mississauga, ON L5N 1A6

References

1. Mann JG, Brown WR, Kern F Jr. The subtle and variable clinical expressions of gluten-induced enteropathy (adult celiac disease, nontropical sprue). An analysis of twenty-one consecutive cases. *Am J Med* 1970;48:357-66.
2. Cooke WT, Homes GKT. *Coeliac disease*. New York: Churchill Livingstone, 1984.
3. Ferguson A. Coeliac disease (gluten hypersensitivity). *J Hum Nutr* 1976;30:193-201.
4. Logan RFA, Tucker G, Rifkin EA, Heading RC, Ferguson A. Changes in clinical features of coeliac disease in adults in Edinburgh and the Lothians, 1960-79. *BMJ* 1983;286:95-7.
5. Swinson CM, Levi AJ. Is coeliac disease underdiagnosed? *BMJ* 1980;281:1258-60.
6. Campbell JA. Diet therapy of coeliac disease and dermatitis herpetiformis. *World Rev Nutr Diet* 1987;51:189-233.

Naprosyn SR

Naprosyn (naproxen)

Prescribing Information:

Therapeutic Classification: Anti-inflammatory, analgesic and antipyretic agent. **Indication:** The treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and juvenile rheumatoid arthritis. **Contraindications:** Naprosyn should not be given to patients with active peptic ulcer or active inflammatory disease of the gastrointestinal tract. It is also contraindicated for those who have shown a sensitivity to it and for patients in whom ASA or other NSAIDs induce the syndrome of asthma, rhinitis or urticaria. Sometimes severe and occasionally fatal anaphylactoid reactions have occurred in such individuals. Suppositories should not be given to patients under 12 years of age or those with inflammatory lesions of the rectum or anus. **Warnings:** Peptic ulceration, perforation and gastrointestinal bleeding, sometimes severe and occasionally fatal have been reported during therapy with NSAIDs, including Naprosyn.

Naprosyn should be given under close supervision to patients prone to gastrointestinal tract irritation particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal tract. Patients taking any NSAID should be instructed to contact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding. These reactions can occur without warning at any time during the treatment. Elderly, frail and debilitated patients appear to be at higher risk from a variety of adverse reactions from NSAIDs. For such patients, consideration should be given to a starting dose lower than usual.

The safety of Naprosyn in pregnancy and lactation has not been established and its use is therefore not recommended.

Precautions: Naprosyn (naproxen) should not be used concomitantly with the related drug Anaprox (naproxen sodium) since they both circulate in plasma as the naproxen anion. GI system: If peptic ulceration is suspected or confirmed, or if gastrointestinal bleeding or perforation occurs Naprosyn should be discontinued, and appropriate treatment instituted. Renal effects: Patients with impaired renal function, extracellular volume depletion, sodium restrictions, heart failure, liver dysfunction, those taking diuretics, and the elderly are at greatest risk of developing overt renal decompensation. Assessment of renal function in these patients before and during therapy is recommended. Naprosyn and its metabolites are eliminated primarily by the kidneys, and therefore, a reduction in daily dosage should be anticipated to avoid the possibility of drug accumulation in patients with significantly impaired renal function. Peripheral edema has been observed, consequently, patients with compromised cardiac function should be kept under observation when taking Naprosyn.

Naprosyn Suspension contains sodium chloride (20 mg/mL). This should be considered in patients whose overall intake of sodium must be restricted.

As with other drugs used with the elderly or those with impaired liver function it is prudent to use the lowest effective dose. Severe hepatic reactions including jaundice, and cases of fatal hepatitis have been reported with NSAIDs. The prescriber should be alert to the fact that the anti-inflammatory, analgesic and antipyretic effects of Naprosyn may mask the usual

signs of infections. Periodic liver function tests and ophthalmic studies are recommended for patients on chronic therapy. Caution should be exercised by patients whose activities require alertness if they experience drowsiness, dizziness, vertigo or depression during naproxen therapy. Naprosyn may displace other albumin-bound drugs from their binding sites and may lead to drug interactions or interfere with certain laboratory tests. See Product Monograph for specific examples.

ADVERSE REACTIONS - (1) Denotes incidence of reported reaction between 3% and 9%. (2) Denotes incidence of reported reactions between 1% and 3%. See Product Monograph for reactions occurring in less than 1% of patients. **Gastrointestinal:** Heartburn (1), constipation (1), abdominal pain (1), nausea (1), diarrhea (2), dyspepsia (2), stomatitis (2), diverticulitis (2). Rectal burning (1) has been reported occasionally with the use of naproxen suppositories.

Central Nervous System: Headache (1), dizziness (1), drowsiness (1), lightheadedness (2), vertigo (2), depression (2), and fatigue (2). **Skin:** Pruritus (1), ecchymoses (1), skin eruptions (1), sweating (2), and purpura (2). **Cardiovascular:** Dyspnea (1), peripheral edema (1), and palpitations (2). **Special senses:** Tinnitus (1), and hearing disturbances (2). **Others:** Thirst (2).

DOSAGE AND ADMINISTRATION

Adult: Oral: The usual total daily dosage for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis is 500 mg (20 mL, 4 teaspoons) a day in divided doses. It may be increased gradually to 750 or 1000 mg or decreased depending on the patient's response. Patients with rheumatoid arthritis or osteoarthritis maintained on a dose of 750 mg/day in divided doses can be switched to a once daily dose of Naprosyn SR 750 mg. The single daily dose of Naprosyn SR should not be exceeded and can be administered in the morning or evening. Naprosyn SR tablets should be swallowed whole. **Rectal:** Naprosyn Suppositories (500 mg) can replace one of the oral doses in patients receiving 1000 mg of Naprosyn daily. **Juvenile Rheumatoid Arthritis:** The recommended daily dose is approximately 10 mg/kg in two divided doses.

AVAILABILITY - Naprosyn is available as: 125 mg, 250 mg, 375 mg, and 500 mg Tablets, as 750 mg Sustained-Release Tablets and 500 mg Suppositories.

Suspension: Each 5 mL contains 125 mg of naproxen. Shake bottle gently before use. Pharmacists are to provide the Naprosyn Patient Information leaflet when dispensing this drug. Product Monograph available to health professionals upon request.

References: 1. Allen, B. et al., *New Zealand Medical Journal* (1989)102(870): 310-312. 2. Ling, T.L. et al., *Journal of Clinical Pharmacology* (1987)27:325-329.

 SYNTEX

PAAB
CCPP

Syntex Inc. * Mississauga (Ontario) Montréal (Québec)

ONCE-A-DAY
Naprosyn SR



7. Green PA, Wollaeger EE. The clinical behavior of sprue in the United States. *Gastroenterology* 1960;38:399-418.
8. Campbell CB, Roberts RK, Cowen AE. The changing clinical presentation of coeliac disease in adults. *Med J Aust* 1977;1:89-93.
9. Gregory C, Ashworth M, Eade OE, Holdstock G, Smith CL, Wright R. Delay in diagnosis of adult coeliac disease. *Digestion* 1983;28:201-4.
10. Campbell JA, Molloy MK, Davidson AGF, Mortimer-Bankier L. Dietary aspects from National Survey of Persons with Coeliac Disease and Dermatitis Herpetiformis. *J Can Diet Assoc* 1991;52:161-5.
11. Biemond I, Pena AS, Groenland F, Mulder CJJ, Tytgat GNJ. Coeliac disease in the Netherlands: demographic data of a patient survey among the members of the Dutch Coeliac Society. *Neth J Med* 1987;31:263-8.
12. Carrington JM. Coeliac disease: an analysis of Coeliac Society membership records. *N Z Med J* 1986;99:279-81.
13. Guandalini S, Ventura A, Ansaldi N, Giunta AM, Greco L, Lazzari R, et al. Diagnosis of coeliac disease: time for a change? *Arch Dis Child* 1989;64:1320-5.
14. Garst PM. *Results of the 1983 Coeliac-Sprue Adult Survey. Proceedings of the Midwest Coeliac Sprue Association Conference.* Mimeo report. Des Moines: Midwest Coeliac Sprue Association, 1984:9.
15. Juby LD, Rothwell J, Axon ATR. Cellobiose/mannitol sugar test - a sensitive tubeless test for coeliac disease: results on 1010 unselected patients. *Gut* 1989;30:476-80.
16. Burgin-Wolff A, Berger R, Gaze H, Hubes H, Lentze MJ, Mussle D, IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study. *Eur J Pediatr* 1989;148:496-502.
17. Calabuig M, Torregosa R, Polo P, Tuset L, Tomas C, Alvarez V, et al. Serological markers and coeliac disease: a new diagnostic approach. *J Pediatr Gastroenterol Nutr* 1990;10:435-42.

• • •